Septest
Latest round
- Seed
Last raised
- Mar 2026
Total raised
- $1.5M
Investors
- 3
About Septest
Founded in 2022 by CTO Alistair Wilson and based in UK, Septest Limited operates as a provider of point-of-care diagnostic tests for detecting infections, inflammation, and sepsis in hospital, primary care, and community healthcare settings. As of October 2026, Jag Grewal is the CEO of the company. Septest is a biotechnology and medical diagnostics company developing rapid point-of-care diagnostic tests for the early detection of infections and inflammatory conditions. Its lead product, TRISEP, is a frontline infection intelligence test designed to provide rapid insight into infection and inflammation in pre-hospital, community, general practice, and hospital settings. The company's solutions focus on improving the diagnosis and management of sepsis, infections, antimicrobial resistance (AMR), pneumonia, tuberculosis, COVID-related conditions, autoimmune diseases, and other inflammatory disorders. Septest aims to provide low-cost, accessible diagnostic tools that enable healthcare professionals to make faster treatment decisions and improve patient outcomes. Once commercialized, the company is expected to generate revenue through the sale of TRISEP diagnostic tests, point-of-care infection testing kits, diagnostic consumables, healthcare provider contracts, hospital and clinic procurement agreements, and licensing of its diagnostic technologies. Additional revenue opportunities may include partnerships with healthcare systems, distributors, public health agencies, pharmaceutical companies, and global health organizations, along with recurring revenue from diagnostic test usage, device deployment, and infection-monitoring programs. The company's long-term business model is centered on commercializing rapid infection and inflammation diagnostics for hospitals, primary care providers, community healthcare settings, and emerging markets.
Who invested in Septest
3 investors across 1 round
See all investors in Septest
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Mar 31, 2026
Amount
$1.5M
Investors
Questions about Septest
Who invested in Septest?
Septest has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Septest raised?
Septest has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Septest last raise money?
Septest's most recent round on record is a Seed, in Mar 2026.
What does Septest do?
Founded in 2022 by CTO Alistair Wilson and based in UK, Septest Limited operates as a provider of point-of-care diagnostic tests for detecting infections, inflammation, and sepsis in hospital, primary care, and community healthcare settings.
Where is Septest headquartered?
Septest is headquartered in Hertford, UK.
Which VCs invest in companies like Septest?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back medical devices & equipment companies at Septest's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Seed
Raising like Septest? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.